1Y Close · As of Aug 26, 2026
WooGeneB&GCO operates in the Pharmaceuticals sector.
Legal name: WooGeneB&GCO.,Ltd
In fiscal year 2025, WooGeneB&GCO (018620) reported revenue of 54.8 billion KRW, down 1.6% from 55.7 billion KRW a year earlier.
Operating profit was 319 million KRW and net income was -3.6 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 19.1 billion KRW, with a P/B of 0.30.
These figures can be verified in the DART filing (receipt no. 20260319001070).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 54.8B | 319M | -3.6B |
| 2024 | 55.7B | 295M | -3.8B |
| 2023 | 57.9B | 714M | -1.2B |
Recent Filings
Officer/Major Shareholder Ownership Report
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Checks
2 of 8 checked items currently applicable.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-25 | Officer/Major Shareholder Ownership Report |
| 2026-08-25 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-07-31 | Officer/Major Shareholder Ownership Report |
| 2026-07-31 | Large Shareholding Report (General) |